J. B. Chemicals & Pharmaceuticals Limited - Balance (Quarterly)

J. B. Chemicals & Pharmaceuticals Limited
IN ˙ BSE
2.048,10 ₹ ↓ -14,85 (-0,72%)
2026-04-30
DEL PRIS
Balance (Quarterly)

J. B. Chemicals & Pharmaceuticals Limited Balance viser kontosaldi for virksomheden på tidspunkter. Balancedata inkluderer aktiver, omsætningsaktiver, anlægsaktiver, materielle anlægsaktiver (PPE), inventar, immaterielle aktiver, passiver, kortfristede forpligtelser, gæld, kapitalleasingforpligtelser, almindelige aktier, overført overskud, egne aktier og egenkapital.

Alle tal er gange 1,000,000.00 undtagen pr. andel enheder.

2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
2025
09-30
Kontanter 377 565 907 769 932 882 975 1.151 1.043
Ændring (%) 50,17 60,39 -15,17 21,14 -5,35 10,48 18,09 -9,36
Aktiver Nuværende 17.193 12.532 15.408 15.280 17.580 18.533 19.133 19.227 25.551
Ændring (%) -27,11 22,95 -0,83 15,05 5,43 3,23 0,49 32,89
Aktiver 24.169 26.074 32.067 35.539 37.992 39.941 40.294 42.738 47.124
Ændring (%) 7,88 22,98 10,83 6,90 5,13 0,88 6,06 10,26
Forpligtelser 4.334 4.688 8.914 10.735 10.825 10.708 8.172 8.405 9.067
Ændring (%) 8,16 90,15 20,43 0,84 -1,08 -23,68 2,85 7,88
Egenkapital 19.834 21.386 23.153 24.804 27.167 29.233 32.122 34.333 38.057
Ændring (%) 7,82 8,26 7,13 9,53 7,61 9,88 6,88 10,85
Passiver og Aktiekapital 24.169 26.074 32.067 35.539 37.992 39.941 40.294 42.738 47.124
Ændring (%) 7,88 22,98 10,83 6,90 5,13 0,88 6,06 10,26

Source: Capital IQ

Other Listings
IN:JBCHEPHARM 2.048,10 ₹
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista